Biophrama Company XTL Files For $40M Offering On Nasdaq

March 10, 2014 | Israeli company XTL Biopharmaceuticals, which is focused on developing a treatment for lupus, has filed with the US Securities and Exchange Commission (SEC) to hold a public offering on Nasdaq in an attempt to raise $40 million. The proceeds will be directed towards various clinical trials the company is planning.